NCT07645313Not yet recruiting
Accuracy and Safety of Anytime 5Pro and Anytime 4Pro CGM Systems in Adults With Diabetes
Accuracy and Safety Evaluation of the Anytime 5Pro and Anytime 4Pro Continuous Glucose Monitoring Systems in Adults With Diabetes: A Post-Market Clinical Follow-up Investigation
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
This post-market clinical follow-up (PMCF) investigation evaluates the accuracy and safety of two CE-marked continuous glucose monitoring (CGM) systems, the Anytime 5Pro and the Anytime 4Pro, in adults with type 1 or type 2 diabetes. Each participant simultaneously wears one Anytime 5Pro sensor and one Anytime 4Pro sensor, one on each upper arm, for the full labelled wear period of each device (up to 16 and 15 days, respectively). CGM readings are compared against venous blood glucose measured by a laboratory reference analyzer (YSI 2500) during four in-clinic sampling sessions that include controlled glucose manipulation. Participants are masked to real-time CGM readings throughout the study. The investigation is conducted to confirm device performance and safety under real-world conditions of use in a European population, in line with the manufacturer's post-market clinical follow-up obligations under the EU Medical Device Regulation.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 8 Jun 2026
- Start date
- 20 Jul 2026
- Primary completion date
- 31 Jan 2027
- Lead sponsor
- Yuwell Group
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT07645313
What you commit to
- Study type: Interventional
- Planned participants: 70
- From 20 Jul 2026 to the primary completion date, 31 Jan 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of medications known to interfere with CGM readings, including ascorbic acid (vitamin C) supplementation \>1000 mg/day.
- Concurrent participation in another interventional device or drug trial, or participation within the past 30 days.
- Known drug or alcohol abuse.
- Planned magnetic resonance imaging (MRI), computed tomography (CT), X-ray examination, or diathermic therapy during the sensor wear period.
- \-
Other illness
- Skin disorders at the prospective sensor insertion site (posterior-lateral upper arm), including scarring, redness, swelling, infection, or tattoos.
- Known allergies to alcohol-based disinfectants or medical adhesives.
- Coagulation abnormalities or bleeding disorders, or current use of anticoagulant therapy (except low-dose aspirin).
- Severe hepatic or renal insufficiency.
- Any condition that, in the judgement of the investigator, would make the subject unsuitable for participation in this investigation or would compromise the subject's safety.
Lab values
- History of epilepsy or psychiatric disorders that may compromise investigation compliance or subject safety during glucose manipulation procedures.
Other
- Current pregnancy, suspected pregnancy, or lactation.
Who the study is looking for
- Diagnosis of type 1 or type 2 diabetes mellitus, documented in medical records, with diabetes established at least 6 months prior to Day 1.
- Age \>= 18 years at the time of informed consent.
- Stable vital signs at screening (systolic blood pressure 90-180 mmHg, diastolic blood pressure 50-110 mmHg, heart rate 50-100 bpm, body temperature 35.5-37.5 C).
- Feasibility of establishing forearm venous access for repeated blood sampling.
- Haematocrit \<= 70%.
- For T1D participants: prior experience with a CGM system (any brand).
- Willingness and ability to comply with the investigation procedures, including wearing both sensors (one Anytime 5Pro and one Anytime 4Pro) simultaneously throughout the 17-day participation period, attending six scheduled clinic visits, and participating in glucose manipulation procedures.
- Written informed consent obtained prior to any investigation-related procedures.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.